(16 August 2010) An independent NGO Health Action International (HAI) Europe published research based on a survey on levels of financial disclosure and transparency among patient and consumer organisations at the European Medicines Agency (EMA). The main findings and key conclusions:
- Two-thirds of the patient and consumer organisations working with the European Medicines Agency (EMA) received partial or significant funding from pharmaceutical manufacturers and/or industry associations. This baseline data suggests that the pharmaceutical industry is the most prevalent sponsor of the patient voice at the EMA.
- Fewer than half of the 23 organisations complied with EMA financial reporting guidelines, which indicates the failure of the EMA to effectively monitor and enforce its own guidelines on financial transparency. EPSU and many other organizations joined in the Alter-EU coalition are campaigning for clearer transparency rules at EU level.
- For more information on the work of that coalition: www.alter-eu.org
- the Fact sheet
And the Website
Health Action International (HAI) is an independent, global network working to increase access to essential medicines and improve their rational use through research excellence and evidence-based advocacy.
- Log in to post comments
